Development of a Highly Effective Bifunctional Ligand 2E‐ C ‐NETA for Targeted Lu‐177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution
ChemMedChem · 15.06.2026 · 21 (11)
DOI: 10.1002/cmdc.70325 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 16.06.2026. Verfasst von Yenwei Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Chelating Agents, Radiopharmaceuticals. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIH.
Abstract (Originalsprache)
Lutetium‐177 is a β‐particle‐emitting radionuclide widely used in targeted radionuclide therapy (TRT). The recent FDA approvals of 177 Lu‐based radiopharmaceuticals including Lutathera and Pluvicto have accelerated research efforts to develop more effective TRT agents. A critical component for the generation of effective 177 Lu radiopharmaceuticals is a bifunctional chelator that can rapidly and stably sequester 177 Lu under mild labeling conditions. Herein, we introduce a novel bifunctional chelator (2E‐ C ‐NETA) for applications in 177 Lu‐based TRT. The chelator 2E‐ C ‐NETA was synthesized and evaluated for radiolabeling efficiency with 177 Lu. 2E‐ C ‐NETA rapidly bound 177 Lu at room temperature, and the resulting complex exhibited excellent serum stability for over 2 weeks. To demonstrate its utility in antibody‐targeted radionuclide therapy, the chelator was further structurally modified for conjugation to Herceptin, an FDA‐approved monoclonal antibody for metastatic breast cancer. The 2E‐ C ‐NETA‐Herceptin conjugate was also rapidly labeled with 177 Lu at room temperature. The 177 Lu‐labeled 2E‐ C ‐NETA‐Herceptin conjugate displayed high stability in human serum for 2 weeks. In mice bearing human colorectal carcinoma (LS‐174T) tumors, 177 Lu‐2E‐ C ‐NETA‐Herceptin demonstrated favorable biodistribution, showing fast blood clearance, minimal uptake in normal tissues, and significant and prolonged tumor accumulation. In summary, these results support 2E‐C‐NETA as a promising bifunctional chelator for the development of 177 Lu‐based radiopharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Illinois Institute of Technology, Chicago, Illinois, USA.
- Department of Radiation Oncology, Washington University, Saint Louis, Missouri, USA.
ORCID-Profile: Hyun-Soon Chong
Förderung
- NIH HHS
- NIH
Zitieren
APA
Chen, Y., Lee, Y., Kang, C. S., Ren, S., Chen, Y., Wang, H., Bandara, N., Rogers, B. E., & Chong, H. S. (2026). Development of a Highly Effective Bifunctional Ligand 2E‐ C ‐NETA for Targeted Lu‐177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution. ChemMedChem, 21(11). https://doi.org/10.1002/cmdc.70325
Vancouver
Chen Y, Lee Y, Kang CS, Ren S, Chen Y, Wang H, et al. Development of a Highly Effective Bifunctional Ligand 2E‐ C ‐NETA for Targeted Lu‐177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution. ChemMedChem. 2026;21(11). doi:10.1002/cmdc.70325
BibTeX
@article{Chen2026,
author = {Chen, Yenwei and Lee, Yeseul and Kang, Chi Soo and Ren, Siyuan and Chen, Yu and Wang, Haixing and Bandara, Nilantha and Rogers, Buck E and Chong, Hyun-Soon},
title = {Development of a Highly Effective Bifunctional Ligand 2E‐ C ‐NETA for Targeted Lu‐177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {11},
doi = {10.1002/cmdc.70325}
}
EUVIMED